Overview

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Status:
Not yet recruiting

Trial end date:
2023-12-29

Target enrollment:

Participant gender:

Summary

This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in subjects with PMR.

Phase:

Phase 2

Details

Lead Sponsor:

Sparrow Pharmaceuticals

Treatments:

Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate